Component
Diabetic polyneuropathy Total Symptom Score / TSS
Diabetic polyneuropathy Total Symptom Score / TSS. Species, exposure and limitations are retained in each linked claim.
2 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
What acts on it
ALADIN III found no significant between-group TSS change at day 19 or after seven months, although an early daily-score area-under-curve analysis favored ALA.
Experimental context and source evidence
- evidence_span
- {"source_cache": "artifacts/ala-research/10480774.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "d28f04985ace61dd6036ea4d08d84e59c47ba587cea6438b7851e036abc1c673", "start_char": 0, "end_char": 2880, "text_sha256": "d28f04985ace61dd6036ea4d08d84e59c47ba587cea6438b7851e036abc1c673"}
- experimental_model
- ALADIN III multicenter randomized placebo-controlled trial
- exposure
- Three weeks intravenous treatment followed by six months oral ALA 600 mg three times daily or comparator sequences
- limitations
- Different route, duration and design from SYDNEY 2; preserve daily-score AUC and final-visit findings separately.
- nutrient_topic
- Alpha-lipoic acid research collection; topical membership is not evidence of a direct dietary effect. · Lipoic acid
- organism
- Human
- plain_language
- The result depended partly on which symptom analysis and time point were examined.
- primary_references
- [ala-p10480774] Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy. (1999). https://pubmed.ncbi.nlm.nih.gov/10480774/ DOI: 10.2337/diacare.22.8.1296
- tissue_or_cell_type
- 509 people with type 2 diabetes and symptomatic polyneuropathy
Alpha-lipoic acid: cofactor assembly, redox signaling and nutrient interactions (2026-09-17) · lines 1144–1155
AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · ALADIN III multicenter randomized placebo-controlled trial · source_derived_draft · unverified_draft
### ala-aladin3-final-tss-null ALADIN III found no significant between-group TSS change at day 19 or after seven months, although an early daily-score area-under-curve analysis favored ALA. Condition category: normal nutrient_topic: Alpha-lipoic acid research collection; topical membership is not evidence of a direct dietary effect. plain_language: The result depended partly on which symptom analysis and time point were examined. organism: Human tissue_or_cell_type: 509 people with type 2 diabetes and symptomatic polyneuropathy experimental_model: ALADIN III multicenter randomized placebo-controlled trial limitations: Different route, duration and design from SYDNEY 2; preserve daily-score AUC and final-visit findings separately. exposure: Three weeks intravenous treatment followed by six months oral ALA 600 mg three times daily or comparator sequences evidence_span: {"source_cache": "artifacts/ala-research/10480774.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "d28f04985ace61dd6036ea4d08d84e59c47ba587cea6438b7851e036abc1c673", "start_char": 0, "end_char": 2880, "text_sha256": "d28f04985ace61dd6036ea4d08d84e59c47ba587cea6438b7851e036abc1c673"} [ala-p10480774] Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy. (1999). https://pubmed.ncbi.nlm.nih.gov/10480774/ DOI: 10.2337/diacare.22.8.1296
Complete structured claim and evidenceIn SYDNEY 2, TSS fell by 4.9, 4.5 and 4.7 points in the 600-, 1200- and 1800-mg groups versus 2.9 with placebo over five weeks.
Experimental context and source evidence
- evidence_span
- {"source_cache": "artifacts/ala-research/17065669.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "3a54016cad3453fec96e99aa5906435793d7baaddaf5254d5ce335aac5bb4519", "start_char": 0, "end_char": 1756, "text_sha256": "3a54016cad3453fec96e99aa5906435793d7baaddaf5254d5ce335aac5bb4519"}
- experimental_model
- SYDNEY 2 randomized double-blind placebo-controlled trial
- exposure
- Oral ALA 600, 1200 or 1800 mg/day for five weeks
- limitations
- Short-term symptom endpoint; no proof of nerve regeneration, lifelong benefit or correction of a nutritional deficiency.
- nutrient_topic
- Alpha-lipoic acid research collection; topical membership is not evidence of a direct dietary effect. · Lipoic acid
- organism
- Human
- plain_language
- This short trial found greater symptom-score improvement with ALA.
- primary_references
- [ala-p17065669] Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. (2006). https://pubmed.ncbi.nlm.nih.gov/17065669/ DOI: 10.2337/dc06-1216
- tissue_or_cell_type
- 181 participants with diabetic distal symmetric polyneuropathy
Alpha-lipoic acid: cofactor assembly, redox signaling and nutrient interactions (2026-09-17) · lines 1118–1129
AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · SYDNEY 2 randomized double-blind placebo-controlled trial · source_derived_draft · unverified_draft
### ala-sydney2-tss In SYDNEY 2, TSS fell by 4.9, 4.5 and 4.7 points in the 600-, 1200- and 1800-mg groups versus 2.9 with placebo over five weeks. Condition category: normal nutrient_topic: Alpha-lipoic acid research collection; topical membership is not evidence of a direct dietary effect. plain_language: This short trial found greater symptom-score improvement with ALA. organism: Human tissue_or_cell_type: 181 participants with diabetic distal symmetric polyneuropathy experimental_model: SYDNEY 2 randomized double-blind placebo-controlled trial limitations: Short-term symptom endpoint; no proof of nerve regeneration, lifelong benefit or correction of a nutritional deficiency. exposure: Oral ALA 600, 1200 or 1800 mg/day for five weeks evidence_span: {"source_cache": "artifacts/ala-research/17065669.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "3a54016cad3453fec96e99aa5906435793d7baaddaf5254d5ce335aac5bb4519", "start_char": 0, "end_char": 1756, "text_sha256": "3a54016cad3453fec96e99aa5906435793d7baaddaf5254d5ce335aac5bb4519"} [ala-p17065669] Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. (2006). https://pubmed.ncbi.nlm.nih.gov/17065669/ DOI: 10.2337/dc06-1216
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.